Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV000208186 | SCV000263989 | uncertain significance | Long QT syndrome | 2015-11-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001058883 | SCV001223481 | uncertain significance | Andersen Tawil syndrome; Short QT syndrome type 3 | 2023-08-16 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 423 of the KCNJ2 protein (p.Arg423Gln). This variant is present in population databases (rs745372216, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with KCNJ2-related conditions. ClinVar contains an entry for this variant (Variation ID: 222677). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003298274 | SCV003999789 | uncertain significance | Cardiovascular phenotype | 2023-03-28 | criteria provided, single submitter | clinical testing | The p.R423Q variant (also known as c.1268G>A), located in coding exon 1 of the KCNJ2 gene, results from a G to A substitution at nucleotide position 1268. The arginine at codon 423 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |